Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1024 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2012  |  Volume : 16  |  Issue : 6  |  Page : 1060-1061

Fluorodeoxyglucose PET/CT and Tc99m-Sestamibi scan, dual tracer imaging in evaluation of osteonecrosis of jaw


1 Department of Nuclear Medicine and PET CT, Jaslok Hospital and Research Centre, Mumbai, India
2 Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, India
3 Department of Pediatric and Preventive Dentistry, P.M.N.M. Dental College and Hospital, Bagalkot, India

Date of Web Publication31-Oct-2012

Correspondence Address:
Prathamesh Joshi
Department of Nuclear Medicine and PET CT, Jaslok Hospital and Research Centre, Worli, Mumbai-400 026
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.103051

Rights and Permissions

How to cite this article:
Joshi P, Kulkarni M, Joshi H. Fluorodeoxyglucose PET/CT and Tc99m-Sestamibi scan, dual tracer imaging in evaluation of osteonecrosis of jaw. Indian J Endocr Metab 2012;16:1060-1

How to cite this URL:
Joshi P, Kulkarni M, Joshi H. Fluorodeoxyglucose PET/CT and Tc99m-Sestamibi scan, dual tracer imaging in evaluation of osteonecrosis of jaw. Indian J Endocr Metab [serial online] 2012 [cited 2019 Nov 14];16:1060-1. Available from: http://www.ijem.in/text.asp?2012/16/6/1060/103051

Sir,

We read with great interest the case 'Osteonecrosis of jaw associated with bisphosphonate use' reported by Rastogi et al., in May-June 2012 issue. [1] We congratulate the authors for demonstrating the importance of keeping this diagnosis in mind while evaluating jaw pain.

As the authors point out, Osteonecrosis of jaw (ONJ) is a much more common event in those patients receiving bisphosphonates for the treatment and prevention of cancer-related skeletal events (mainly intravenously), rather than in those patients receiving bisphosphonates (mainly orally) for nonmalignancy indications. [1] We would like to draw the readers' attention to a nuclear medicine approach that can be useful to evaluate jaw pain and differentiate ONJ from neoplastic conditions affecting the jaw in patients known to have cancer. Histology is in some cases mandatory to differentiate ONJ from neoplastic osteolysis, but a biopsy can further contribute to bone damage. Hence the noninvasive imaging approach is worth describing.

Nuclear medicine functional imaging obtained by a tracer that shows oncotropic properties, such as Tc99m-sestamibi, in comparison to a nontumor-specific tracer such as fluorodeoxyglucose (FDG), can support the differential diagnosis, thus avoiding invasive procedures in diagnosis of ONJ. [2],[3]

FDG is an exquisitely sensitive agent for tumor imaging with high negative predictive value; however, it is also known to be nonspecific and can sometimes show uptake in nonmalignant, infective/inflammatory pathology. [4] While Tc99m-sestamibi is considered to be a tumor-specific agent. The dual tracer approach is based on the criteria that malignant pathology causing jaw pain will be FDG as well as Tc99m-sestamibi avid. Alternatively, nonmalignant causes like ONJ, will be FDG avid but will be cold on Tc99m-sestamibi scan.

This criteria has been primarily studied in differentiating ONJ from myeloma involving mandible. [2],[5] Dual tracer imaging is an interesting approach to diagnose/exclude diagnosis of ONJ avoiding the risks of a surgical biopsy.

 
   References Top

1.Rastogi A, Rattan V, Bhadada SK. Osteonecrosis of jaw associated with bisphosphonate use. Indian J Endocrinol Metab 2012;16:450-2.  Back to cited text no. 1
[PUBMED]    
2.Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, et al. Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Ann Hematol 2007;86:415-23.  Back to cited text no. 2
[PUBMED]    
3.Morag Y, Morag-Hezroni M, Jamadar DA, Ward B, Jacobson J, Zwetchkenbaum S, et al. Bisphosphonate-related osteonecrosis of the jaw: A pictorial review. Radio Graphics 2009;29:1971-84.  Back to cited text no. 3
    
4.Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evalutaion of cancer patients. Radio Graphics 2003;23:315-40.  Back to cited text no. 4
    
5.Rangarajan V, Purandare N, Sharma A. Evidence Based Management of Cancers in India. Vol. 8. India: Tata Memorial Hospital; 2009. p. 34-5.  Back to cited text no. 5
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed997    
    Printed19    
    Emailed0    
    PDF Downloaded203    
    Comments [Add]    

Recommend this journal